|
|
|
|
||
Re: Independent Analyst update with details There is a great deal of information compiled there and well worth reading. One comment I would make though, it seems a little disingenuous to refer to Alnylam's ESC platform drugs as retired or obsolete when many of them may result in approved drugs. The previous ARWR platform was retired due to safety issues and no drugs will be approved. Not exactly a fair comparison. See the Platforms page for reference. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
10001 | Re: Independent Analyst update with details | Aspector | 6 | 5/31/2019 1:05:52 PM |